Glycation of apoB (apolipoprotein B) of LDL (low-density lipoprotein) increases its atherogenicity. Concentrations of both serum glyc-apoB (glycated apoB) and SD-LDL (small dense LDL) (syn LDL3; D = 1.044-1.063 g/ml) are increased in diabetes and are closely correlated. We studied whether SD-LDL is more susceptible to glycation in vitro than more buoyant LDL in statin-and non-statin-treated Type 2 diabetes mellitus. Serum SD-LDL apoB and glyc-apoB on statins was 20 + − 2 (means + − S.D.) and 3.6 + − 0.41 compared with 47 + − 3 and 5.89 + − 0.68 mg/dl in those not receiving statins (P < 0.001 and <0.01, respectively). There was a dose-dependent increase in glycation on incubation of LDL subfractions with glucose, which was accompanied by an increase in LPO (lipid peroxide) and electrophoretic mobility and a decrease in free amino groups. SD-LDL was more susceptible to these changes than more buoyant LDL. Both SD-LDL and more buoyant LDL from statin-treated patients were less susceptible to glycation. There were fewer free amino groups on LDL subfractions from statin-treated patients, which may contribute to this resistance. In conclusion, greater susceptibility of SD-LDL to glycation is likely to contribute to the raised levels of circulating glyc-apoB in diabetes. Statins are associated with lower levels of both SD-LDL and glyc-apoB.
INTRODUCTION
LDL (low-density lipoprotein) is strongly related to the risk of CHD (coronary heart disease) in Type 2 diabetes mellitus [1] . LDL is heterogeneous and smaller, denser subfractions have been reported to be the most closely associated with CHD [2] [3] [4] . The most frequently advanced explanation for this is that SD-LDL (small dense LDL) is more susceptible to oxidative modification than the more buoyant LDL subfractions [5, 6] . The latter are larger and more lipid-rich. Thus more of the single molecule of apoB (apolipoprotein B) present in all LDL particles is buried within its non-polar lipid domains. Therefore it is more likely to escape surface exposure where, for example, aldehydes and ketones released from oxidized glycerophospholipids, such as phosphatidylcholine, can for man adduct with the free amino groups of lysine residues [7, 8] . This predisposes apoB to fragmentation which converts it into a ligand for the scavenger receptAbbreviations: apoB, apolipoprotein B; CHD, coronary heart disease; CHOD, cholesterol oxidase; glyc-apoB, glycated apoB; HDL-c, high-density lipoprotein-cholesterol; HRP , horseradish peroxidase; LDL, low-density lipoprotein; LDL1&2, LDL1 and LDL2 subfractions; LPO, lipid peroxide; PAP , phosphatidic acid phosphohydrolase; REM, relative electrophoretic mobility; SD-LDL, small dense LDL; TAG, triacylglycerol; TNBS, trinitrobenzenesulfonic acid.
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ors of arterial wall macrophages and the formation of macrophage foam cells central to atherosclerosis [9, 10] .
Oxidation is not, however, the only naturally occurring modification of LDL that can promote rapid uptake by macrophages. Glycation of apoB in which glucose is covalently bonded with the free amino groups of lysine also does so [11] . Comparison of the relative proportions of oxidized and glycated LDL in the human circulation is difficult because the assay for oxidized LDL most widely used measures oxidized phospholipids on LDL rather than the amount of oxidatively modified apoB (the major component of its protein moiety) [12, 13] . However, it is likely that the serum glyc-apoB (glycated apoB) concentration exceeds that of oxidatively modified apoB. Serum concentrations of glyc-apoB are typically in the range 2-10 mg/dl in diabetes [14, 15] and glycation of LDL has been reported to increase its susceptibility to oxidative modification [16] . We first reported that in non-diabetic people SD-LDL undergoes more extreme glycation than the more buoyant LDL subfractions both in vivo and in vitro [17] . In a more recent study, we found that in Type 2 diabetes mellitus SD-LDL is the major determinant of the serum concentration of glyc-apoB. We also demonstrated both glycapoB and SD-LDL are lower in diabetic patients treated with statins than in those not receiving such treatment [15] . In the present study, we have investigated the susceptibility of LDL subfractions isolated from patients with Type 2 diabetes mellitus receiving statin treatment and not on statins. We sought to establish whether the process of glycation is accompanied by alterations in these subfractions, such as a decrease in free amino acid groups, accumulation of LPO (lipid peroxide) even in the absence of elemental oxygen or any other source of free radicals other than the glycative process itself and any change in LDL electrophoretic mobility signalling a change in its size and electrical charge.
MATERIALS AND METHODS

Patients
At total of 38 Type 2 diabetic patients, as defined by the WHO (World Health Organization) criteria [18] , were recruited from the Lipid Clinic and the Manchester Diabetes Centre at Central Manchester University Hospitals NHS Foundation Trust. Of these, 26 were receiving simvastatin 40 mg daily or atorvastatin 10-40 mg daily and 12 were not on lipid-lowering medication. There were no clear differences between the groups of diabetic patients studied in terms of hypoglycaemic medications recorded which were typical of Type 2 diabetes mellitus. Thus some 28 % were on no hypoglycaemic agents, 17 % were receiving metformin monotherapy, 3 % sulfonylurea alone, 15 % a combination of metformin and sulfonylurea, 15 % a thiazolidinedione with metformin or sulfonylurea or with a combination of metformin and sulfonylurea and 23 % on insulin alone or combined with oral hypoglycaemic therapy. None of the patients studied was on supplements of ω − 3 fatty acids or fish oil. All patients gave informed consent to the study, which was approved by the Local Research Ethics Committee.
Isolation of lipoproteins
Blood samples were collected between 09.00 and 11.00 h after fasting from 22.00 h the previous day. EDTA-plasma and serum were isolated by centrifugation at 2000 g for 15 min at 4
• C within 2 h of collection and were maintained at that temperature until further use. Serum was used for cholesterol, TAG (triacylglycerol) and HDL-c (high-density lipoprotein-cholesterol) assays and EDTA-plasma for apoA-I, apoB and glyc-apoB assays. EDTAplasma was also subjected to sequential ultracentrifugation in a Beckman L7 ultracentrifuge with a 50.4Ti fixed angle rotor using 13 mm×64 mm polyallomer tubes (34 000 rev./min; 144 361 g for 22 h 17 min) to isolate LDL1&2 (LDL1 and LDL2 subfractions combined) (D = 1.019-1.044 g/ml) and LDL3 (D = 1.044-1.063 g/ml) as described previously [17] . LDL3 is synonymous with SD-LDL and LDL1&2 with more buoyant LDL subfractions. Isolated lipoproteins were subjected to an overnight dialysis in PBS; pH 7.4 at 4
• C.
Glycation of lipoproteins in vitro
Isolated lipoproteins, adjusted to 1 mg of protein/ml, were incubated under N 2 at 37
• C with 30, 50, and 80 mmol/l glucose and no glucose (0, control) in PBS containing 0.02 % NaN 3 without EDTA for 1 week [17] . Following incubation, unbound glucose was removed by overnight dialysis at 4
• C against PBS (pH 7.4). Protein concentration was then determined and 100 μl was applied to the top of the m-aminophenylboronate affinity chromatography column in order to separate glycated and non-glycated proteins [19, 20] . The column (0.5 ml of immobilized boronic acid; Thermo Scientific) was first equilibrated with 10 ml of ammonium acetate wash buffer [250 mmol/l ammonium acetate, 50 mmol/l MgCl 2 , 500 mmol/l NaCl, 3 mmol/l NaN 3 and 0.1 % (v/v) Tween 20, pH 8.5]. The non-glycated proteins were then eluted using 5 ml of ammonium acetate buffer before elution of glycated proteins using 3.9 ml of sorbitol buffer [200 mmol/l sorbitol, 500 mmol/l NaCl, 50 mmol/l Na 2 EDTA, 100 mmol/l Tris/HCl and 0.1 % (v/v) Tween 20, pH 8.5].
Our in-house high-sensitivity ELISA method, based on the antibody sandwich principle, was used to measure apoB in the second chromatography eluate (glycated LDL; glycapoB100). This employs unconjugated and HRP (horseradish peroxidase)-conjugated goat anti-(human apoB) polyclonal antibodies (Abcam) as capture and detection antibodies, respectively. The apoB standard (Sigma) was used in the concentration range of 0.006-0.06 mg/dl. The amount of bound analyte was detected with the HRP-substrate, o-phenylenediamine (Sigma) and the intensity of the colour was measured at 490 nm using a Dynatech MR7000 plate reader. The extent of glycation in LDL and its subfractions are expressed as mg of glyc-apoB in the bound eluate per mg of total protein applied to the boron affinity chromatography column. The ELISA developed for measuring apoB was highly sensitive (detection limit, 4.6×10 − 6 g/l) with and intra-and inter-assay coefficients of variation 5.1 and 8.5 % respectively. Using it to measure glycation after separating glycated from non-glycated LDL showed good recovery even after recycling chromatography columns up to five times. The recovery of glyc-apoB100 ranges from 90 to 103 % and non-glyc-apoB100 from 88 to 93 %.
Agarose gel electrophoresis
Following in vitro glycation, REM (relative electrophoretic mobility) of LDL subfractions on agarose gel electrophoresis was determined using 15 μg of native or glycated lipoproteins under electrophoresis conditions described previously [17] . Gels were visualized under UV light and photographed using a Unipro Platinum gel documentation and analysis system (Uvitec).
Measurement of free amino groups and lipid peroxidation after in vitro glycation
The TNBS (trinitrobenzenesulfonic acid) colorimetric assay [21] was used to measure free non-glycated amino groups following glycation. The method was modified to be suitable for microtitre plate assay. In a 96-well plate, 50 μl of sample was mixed with 50 μl of 4 % NaHCO 3 and 50 μl of 0.1 % TNBS. The wells were flushed with N 2 , sealed, and incubated for 2 h at 37
• C in the dark. Absorbance was measured at 340 nm using a multiscan plate reader (Labsystems). LPO formed during glycation of lipoproteins was assayed using the CHOD (cholesterol oxidase) colorimetric assay [22] .
Other laboratory analyses
Cholesterol and TAG in serum and lipoproteins were determined using CHOD-PAP (where PAP is phosphatidic acid phosphohydrolase) and GPO (glycerol-3-phosphate oxidase)-PAP methods respectively using reagents from ABX Horiba-UK. HDL-c was measured by a direct second-generation homogenous method (Roche Diagnostics). SD-LDL was isolated by ultracentrifugation using the method of Menys et al. [23] . ApoB in serum and SD-LDL and serum apoA-I were assayed using immunoturbidimetric methods (ABX Horiba). A Cobas Mira auto-analyser (ABX Horiba) was employed for all these assays. Plasma glycapoB was measured using glycacore assay kit (Exocell) supplied by Biognosis. Protein content in lipoprotein fractions was determined using the Pierce ® BCA protein assay kit (Fisher Scientific) with BSA as a standard [24] . Plasma glucose was determined using an automated glucose oxidase method in the routine clinical biochemistry laboratory which participates in the UKNEQAS (United Kingdom National External Quality Assessment Service).
Statistical analyses
Assays were performed in duplicate and the average value was used for data analysis. Each of the incubation experiments was repeated 12 times for each LDL subfraction at glucose 0-80 mmol/l for statin-and for non-statin-treated patients. Results were expressed as means + − S.E.M. except for TAG, which had a nonGaussian distribution, for which median and range were used. Statistical analyses of data were done by the Statistical Package for Social Sciences software (SPSS). A Student's t test was used to assess significance of differences with P < 0.05 being taken as statistically significant. TAG data were logarithmically transformed before these analyses.
RESULTS
Characteristics of the patients studied
Type 2 diabetic patients who were not receiving statin treatment had a higher serum cholesterol (P < 0.01), apoB (P < 0.01) and apoA-I (P < 0.05) and plasma LDL-c (LDL-cholesterol) (P < 0.001), SD-LDL (P < 0.001) and glyc-apoB (P < 0.01) compared with those receiving statin treatment ( Table 1) .
Incubation of LDL subfractions with glucose
The absolute values for glyc-apoB, LPO and free amino group content of LDL subfractions isolated from Type 2 diabetic patients who were and were not receiving statin treatment are shown in Table 2 . On incubation of both LDL1&2 combined and LDL3, regardless of statin treatment, there was a graded increase in glycapoB and LPO and a progressive decrease in free amino groups with increasing glucose concentration. In the absence of glucose, glyc-apoB and LPO tended to be higher in patients receiving statins, although this did not achieve significance except in the case of LPO in LDL1&2 (P < 0.001). Free amino group concentration at baseline was, however, significantly lower in statin-treated patients in both LDL1&2 and LDL3 (P < 0.05 and P < 0.001, respectively). The subsequent rises in glyc-apoB and LPO and the decreases in free amino group concentration in patients not receiving statins tended to be greater. This resulted in significantly higher glyc-apoB in LDL3 in non-statin-treated patients at glucose 50 and 80 mmol/l (P < 0.05 and P < 0.01, respectively). The free amino group concentration was less in LDL3 at all glucose concentrations in the statin-treated patients (all P < 0.01). The percentage changes in glyc-apoB, LPO and free amino groups after incubation of LDL subfractions with increasing concentrations of glucose are shown in Figures 1 and 2 for non-statintreated and statin-treated patients, respectively. The percentage increase in glyc-apoB in LDL3 was consistently greater than in LDL1&2, achieving statistical significance at 80 mmol/l in both statin-and non-statin-treated patients (P < 0.01 and P < 0.001, respectively) and also at 30 mmol/l in those on statins (P < 0.05). The electrophoretic mobility of LDL subfractions increased on incubation. This increase was greater at higher glucose concentrations and for LDL3 as opposed to LDL1&2. Figure 3 shows the increase in electrophoretic mobility of LDL subfractions incubated with glucose 80 mmol/l relative to baseline rates. This relative mobility increase was greater for LDL3 compared with LDL1&2 in both statin-and non-statin-treated patients (P < 0.001) and more in both subfractions of those not receiving statins in contrast with those who were statin-treated (P < 0.05 for both LDL1&2 combined and for LDL3).
DISCUSSION
Post-translational non-enzymatic protein glycation occurs as a consequence of the glycation of the free amino groups of lysine Table 2 Glycated LDL apoB (mg/mg protein), lipid peroxides (μmol/l) and free amino groups (g/l) following glycation in vitro Glycated LDL apoB, LPO and free amino groups at baseline (0) and following glycation in vitro (30-80 mmol/l glucose for 7 days at 37 • C) of LDL1&2 (combined) and LDL3 isolated from patients with Type 2 diabetes mellitus who were and were not receiving statins. Glycated LDL apoB in LDL is expressed as mg of apoB eluted from the m-aminophenlboronate chromatography column with the second (sorbitol) buffer per mg of protein in the LDL fraction applied to the column. Results are shown as means + − S.E.M. (n = 12). * P < 0.05, * * P < 0.01 and * * * P < 0.001 compared with baseline; †P < 0.05, † †P < 0.01 and † † †P < 0.001 compared with the corresponding results in the statin-untreated group. residues [11, 25, 26] . We showed that incubation of LDL subfractions with glucose resulted in concentration-dependent glycation of apoB. Our in vitro experiments also revealed that SD-LDL from patients with Type 2 diabetes is more susceptible to glycation than more buoyant LDL, consistent with our previous results for non-diabetic subjects [17] . This greater susceptibility is likely to occur because a larger proportion of lysine residues of apoB are exposed at the surface of smaller LDL particles. The higher contribution of SD-LDL to the total serum concentration of glyc-apoB compared with that of other LDL subfractions previously reported in vivo [15, 17] may also be because of the longer residence time of SD-LDL in the circulation [27] . The present investigation also extends our previous observations [15, 28] and that of others [29, 30] that the serum concentrations of both SD-LDL and glyc-apoB are lower in statin-treated Type 2 diabetes mellitus. During in vitro glycation, there was a small increase in LDL LPO, even though our experiments were conducted under N 2 with no source of oxygen or other free-radical-generating substances other than glucose. Glycation is itself an oxidative process [31] . However, the quantity of LPO produced even after 7 days of incubation is low compared with those produced when LDL is intentionally oxidatively modified, for example, with copper ions [32] . Nevertheless, in emphasizing the potential role of LDL glycation in atherogenesis, it is not our intention to deny that LDL oxidation also contributes. Both are probably important and the best current means of decreasing both circulating oxidatively modified and glycated LDL is to decrease LDL with statin treatment.
Glucose
Our finding that during incubation of LDL with glucose the free amino groups diminish is consistent with the covalent bonding of glucose and of lipid peroxidation products with exposed amino groups of lysine. The greater decrease in free amino groups in SD-LDL further supports our conclusion that it is more susceptible to glycation as it is to oxidative modification [33, 34] . Addition of glucose and LPO products to apoB of LDL leading to charge alterations and fragmentation are likely to explain the increased electrophoretic mobility of LDL on incubation with glucose and again this effect was most pronounced with SD-LDL.
In our experiments, standard concentrations of LDL1&2 combined and of LDL3 (1 mg of protein/ml) were used. We found that the concentrations of glyc-apoB and LPO were greater in both LDL1&2 combined and LDL3 from statin-treated patients per mg of protein even before incubation with glucose. This is thus likely to have been the case in vivo. This finding does not, however, imply that circulating serum LDL concentrations of glyc-apoB and LPO are higher in statin-treated patients, because the level of circulating LDL was lower in the statin-treated patients. Compatible with this conclusion, the concentration of glyc-apoB was lower in our statin-treated patients. Other studies have shown that the concentrations of LDL LPO, which are increased in non-statin-treated diabetes [35, 36] , are decreased by statin therapy and that too may have a similar explanation [37] . The situation for free amino groups, which were lower basally in the statin-treated patients, is, however, different, because the lower LDL concentrations in statin-treated patients would be expected to reinforce their decreased availability in vivo. Because both glycative and oxidative modification of LDL involves the chemical combination of the exposed free amino groups of lysine of apoB with glucose or lipid peroxidation products, respectively, their relative paucity in the LDL of statin-treated patients could, in addition to the decreased concentration of the more susceptible LDL3, contribute to the resistance of LDL from statin-treated patients to glycation or oxidation. Our finding that both LDL1&2 and LDL3 from statin-treated patients undergo smaller increases in REM on glycation than those of patients not on statins is also likely to reflect the decrease in their free amino groups. This is probably because a higher proportion of the free amino groups in LDL have already combined with glucose or lipid peroxidation products in vivo, because of the decreased LDL pool size. Thus fewer remain to react with glucose and lipid peroxidation products, conferring an apparent resistance.
In the present experiments LDL glycation was accomplished by incubation for 7 days with glucose 30-80 mmol/l under N 2 . We have previously drawn attention to the relative resistance of LDL to glycation in vitro. Supraphysiological concentrations of glucose are required as has been consistently reported [11, 17, 26, 38] . The implication is that glycation occurs more readily in vivo. It has been suggested that glucose metabolites produced in vivo may be more reactive [38, 39] or that LDL may be more susceptible to glycation if it is concurrently reacting with free radicals present at higher concentrations in vivo [40] It may be relevant that SD-LDL is also the subfraction of LDL most susceptible to oxidation [41] . We are in the process of investigating these possibilities further. It is also noteworthy in this connection that all of the potentially atherogenic naturally occurring modifications of LDL by, for example, oxygen-free radicals [8] , glucose [11] or homocysteine [42] , involve the free amino groups of the lysine residues of apoB100, more of which are likely to be exposed at the surface in smaller LDL particles. 
Conclusions
We conclude that, in addition to its susceptibility to oxidation, SD-LDL may be rendered more atherogenic because it is more liable to be glycated than more buoyant LDL in patients with Type 2 diabetes mellitus, as well as non-diabetic individuals. Statins which are effective in decreasing SD-LDL also decrease the susceptibility of the apoB of LDL to undergo glycation by lowering the concentration of SD-LDL in whole LDL.
CLINICAL PERSPECTIVES
r It has been shown previously that a subfraction of LDL, namely SD-LDL, is more closely associated with the development of atherosclerosis than the more buoyant LDL. SD-LDL levels are increased in Type 2 diabetes mellitus and correlate with the extent of glycation of LDL.
r In the present study, we incubated SD-LDL and the more buoyant LDL was isolated from Type 2 diabetes mellitus people with glucose in vitro. SD-LDL underwent more glycation than the more buoyant LDL. In statin-treated patients both SD-LDL and glycated LDL were decreased.
r These lower concentrations of SD-LDL with its greater susceptibility to glycation may explain the decrease in LDL glycation on statin therapy and contribute to the effectiveness of statins in preventing atherosclerotic CVD (cardiovascular disease).
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